Navigation Links
Unlocking mystery of why dopamine freezes Parkinson's patients
Date:8/8/2008

CHICAGO -- Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery.

New research from Northwestern University's Feinberg School of Medicine has revealed that dopamine strengthens and weakens the two primary circuits in the brain that control our behavior. This provides new insight into why a flood of dopamine can lead to compulsive, addictive behavior and too little dopamaine can leave Parkinson's patients frozen and unable to move.

"The study shows how dopamine shapes the two main circuits of the brain that control how we choose to act and what happens in these disease states, " said D. James Surmeier, lead author and the Nathan Smith Davis Professor and chair of physiology at the Feinberg School. The paper is published in the August 8 issue of the journal Science.

These two main brain circuits help us decide whether to act out a desire or not. For example, do you get off the couch and drive to the store for an icy six-pack of beer on a hot summer night, or just lay on the couch?

One circuit is a "stop" circuit that prevents you from acting on a desire; the other is a "go" circuit that provokes you to action. These circuits are located in the striatum, the region of the brain that translates thoughts into actions.

In the study, researchers examined the strength of synapses connecting the cerebral cortex, the region of the brain involved in perceptions, feelings and thought, to the striatum, home of the stop and go circuits that select or prevent action.

Scientists electrically activated the cortical fibers to simulate movement commands and boosted the natural level of dopamine. What happened next surprised them. The cortical synapses connecting to the "go" circuit
'/>"/>

Contact: Marla Paul
marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Unlocking the function of enzymes
2. The key to unlocking the secret of highly specific DNAzyme catalysis
3. Scientists tackle mystery mountain illness
4. Folate mystery finally solved
5. Men shed light on the mystery of human longevity, study finds
6. Magnetic snakes control fluids, gravity-defying droplets, and solving a dragonfly mystery
7. Cassini on the trail of a runaway mystery
8. Time-sharing tropical birds key to evolutionary mystery
9. 480-million-year-old fossil sheds light on 150-year-old paleontological mystery
10. ASU professor helps solve mystery of glassy water
11. Ancient mystery solved
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Study confirms association between tobacco smoke and behavioral problems in children 2The impact of the diffusion of maize to the Southwestern United States 2Small addition to cancer drug may make big difference 2Small addition to cancer drug may make big difference 3Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 1Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 2Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 3Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 4Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 5Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 6Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 7Video 3A Schering Plough Announces FDA Approval of SAPHRIS 28R 29 28asenapine 29 for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Ep 54521 8WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009 54518 1WuXi PharmaTech Selected as One of the Top Ten Employer for New College Graduates in Pharmaceutical Industry in 2009 54518 2Surface Mount Solutions Launches New Website 13561 1Surface Mount Solutions Launches New Website 13561 2